[Initial results of clinical trial of a new long-acting neuroleptic agent: Fluspirelene].
D000293:Adolescent; D000328:Adult; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006846:Hydrocarbons, Halogenated / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*; D010259:Paranoid Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013141:Spiro Compounds / Q000627:therapeutic use*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D006846:Hydrocarbons, Halogenated; D010880:Piperidines; D013141:Spiro Compounds; D014149:Tranquilizing Agents
Primi risultati della sperimentazione clinica di un nuovo neurolettico ad azione prolungata: il Fluspirilene.